Pacer Advisors Inc. Has $638,000 Stock Position in Solventum Corporation $SOLV

Pacer Advisors Inc. cut its holdings in Solventum Corporation (NYSE:SOLV) by 43.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,763 shares of the company’s stock after selling 7,386 shares during the period. Pacer Advisors Inc.’s holdings in Solventum were worth $638,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SOLV. United Services Automobile Association bought a new stake in Solventum during the 1st quarter worth about $239,000. Woodline Partners LP grew its holdings in shares of Solventum by 40.7% in the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after acquiring an additional 3,377 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Solventum by 167.0% in the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after acquiring an additional 10,425 shares in the last quarter. First Trust Advisors LP increased its position in shares of Solventum by 5.8% in the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after acquiring an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Solventum in the second quarter valued at about $766,000.

Solventum Trading Up 2.9%

Shares of SOLV stock opened at $85.38 on Tuesday. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $90.00. The company has a market capitalization of $14.53 billion, a PE ratio of 10.44, a price-to-earnings-growth ratio of 1.06 and a beta of 0.60. The firm has a 50 day moving average price of $79.58 and a two-hundred day moving average price of $74.45. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, analysts predict that Solventum Corporation will post 7.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SOLV. Wells Fargo & Company reduced their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Piper Sandler boosted their price target on Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. UBS Group upped their price objective on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday. Stifel Nicolaus raised their target price on shares of Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen raised shares of Solventum from a “hold” rating to a “buy” rating in a research note on Saturday. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $91.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.